Reasonable amount of chit chat - for obviously positive progress. But it is 'only' progress within our existing phase.
We will likely see more chit chat and SP action when we reach a new level - like progression into the validation trial phase or some sort of positive direction provided by FDA or something to do with distribution deals. Just like when Keysight came on board with its major investment.
Ann: Stage 2 Insights Confirm Diagnostic & Clinical Viability, page-19
Add EMV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.94 |
Change
0.000(0.00%) |
Mkt cap ! $165.7M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4886 | $1.87 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.95 | 102 | 1 |
View Market Depth
| Last trade - 10.22am 12/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.86 |
Change
0.000 ( 3.48 %) |
||||
| Open | High | Low | Volume | ||
| $1.87 | $1.87 | $1.86 | 2979 | ||
| Last updated 10.40am 12/06/2024 ? | |||||
| EMV (ASX) Chart |
Day chart unavailable